Psychemedics Corp (PMD) 15.14 $PMD
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 15.14 (+0.02), ABT: 44.59 (+0.36), A: 41.45 (unch), DHR: 82.40 (+0.04), PKI: 43.54 (-0.24), OSUR: 8.96 (-0.22)
Psychemedics: Recent Results Reflect Risk Of The Brazilian Expansion
Investing Doc - at Seeking Alpha - Tue Nov 04, 7:21AM CST
PMD: 15.14 (+0.02)
Psychemedics EPS of $0.17
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 10:14AM CDT
PMD: 15.14 (+0.02)
Psychemedics Corporation Announces Record Revenues
PR Newswire - Thu Oct 30, 10:06AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced third quarter financial results for the period ended September 30, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of November 10, 2014 to be paid on November 20, 2014. This will be the Company's 73rd consecutive quarterly dividend.
PMD: 15.14 (+0.02)
Psychemedics: Once Brazilian Legislation Is Put Into Place Shares Should Rally
Bram de Haas - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PMD: 15.14 (+0.02)
Psychemedics Has Returned 13.0% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Wed Sep 17, 9:26AM CDT
SmarTrend identified a Downtrend for Psychemedics (NASDAQ
MD) on May 9th, 2014 at $14.87. In approximately 4 months, Psychemedics has returned 13.05% as of today's recent price of $12.93.
PMD: 15.14 (+0.02)
Psychemedics Up 48.7% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Thu Mar 27, 9:38AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 48.74% as of today's recent price of $17.67.
PMD: 15.14 (+0.02)
Psychemedics Shares Up 53.2% Since SmarTrend's Buy Recommendation (PMD)
Comtex SmarTrend(R) - Thu Mar 20, 9:11AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 53.20% as of today's recent price of $18.20.
PMD: 15.14 (+0.02)
Uptrend Call Working As Psychemedics Stock Rises 50.8% (PMD)
Comtex SmarTrend(R) - Wed Mar 12, 4:51PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 50.76% as of today's recent price of $17.91.
PMD: 15.14 (+0.02)
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
PMD: 15.14 (+0.02), BGMD: 0.45 (-0.02), RXDX: 6.76 (+0.04), BRLI: 28.98 (-0.05), DGX: 63.77 (+0.88), GHDX: 32.77 (-0.22)
Psychemedics Up 52.1% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Wed Mar 05, 11:04AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 52.10% as of today's recent price of $18.07.
PMD: 15.14 (+0.02)
OTC Daily Alert Stock Watch - Psychemedics Corporation (NASDAQ: PMD)
WorldStockWire - Mon Sep 02, 10:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
PMD: 15.14 (+0.02)
Psychemedics Corporation Announces Top Revenue Quarter
PR Newswire - Mon Aug 05, 10:36AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2013. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 15, 2013 to be paid on August 28, 2013. This will be the Company's 68th consecutive quarterly dividend.
PMD: 15.14 (+0.02)
Psychemedics Corporation Launches New Hair Alcohol Test
PR Newswire - Mon Jul 08, 12:01PM CDT
Psychemedics Corporation (NASDAQ MD), hair testing pioneer and global leader for over twenty-five years, announced the launch of its hair alcohol test - a test that measures average alcohol consumption over a period of approximately three months, indicates the level of alcohol use during that time period, and can provide a behavioral indication of excessive use.
PMD: 15.14 (+0.02)
Sarah Ashby Promoted To VP And General Counsel At Psychemedics Corporation
PR Newswire - Tue May 14, 10:44AM CDT
Psychemedics Corporation (NASDAQ: PMD), the world's largest provider of hair analysis drug testing, today announced that Sarah Ashby has been promoted to the position of Vice President and General Counsel.
PMD: 15.14 (+0.02)
Psychemedics Corporation announces lower net income of USD822,000, but higher revenues of USD6.4m for Q1
M2 - Wed May 08, 10:28AM CDT
Drug abuse testing company Psychemedics Corporation (NasdaqCM MD) stated on Tuesday its net income of USD822,000 or USD0.16 per diluted share, for the first quarter period ended 31 March 2013.
PMD: 15.14 (+0.02)
Psychemedics Corporation Announces Record First Quarter Revenues
PR Newswire - Tue May 07, 10:33AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2013. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 17, 2013 to be paid on May 30, 2013. This will be the Company's 67th consecutive quarterly dividend.
PMD: 15.14 (+0.02)
Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test
PR Newswire - Thu Feb 28, 10:43AM CST
Psychemedics Corporation, (NASDAQ: PMD) and TruTouch Technologies, Inc. today announced that they have signed an agreement to market TruTouch's rapid optical alcohol detection and biometric test in the US. The workplace sobriety assurance solution utilizes an optical based, non-invasive near infra red sensor that quickly and accurately measures alcohol consumption. This is simply done by placing the index finger on the optical sensor and waiting as few as 10 seconds for the initial results.
PMD: 15.14 (+0.02)
Psychemedics Corporation Announces Record Revenues For 2012; Declares 66th Consecutive Quarterly Dividend
PR Newswire - Mon Feb 25, 10:57AM CST
Psychemedics Corporation (NASDAQ MD) today announced fourth quarter and year-end financial results for the period ended December 31, 2012. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of March 7, 2013 to be paid on March 21, 2013. This will be the Company's 66th consecutive quarterly dividend.
PMD: 15.14 (+0.02)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 15.14 (+0.02), ABT: 44.59 (+0.36), A: 41.45 (unch), DHR: 82.40 (+0.04), PKI: 43.54 (-0.24), OSUR: 8.96 (-0.22)
Psychemedics: Recent Results Reflect Risk Of The Brazilian Expansion
Investing Doc - at Seeking Alpha - Tue Nov 04, 7:21AM CST
PMD: 15.14 (+0.02)
Psychemedics EPS of $0.17
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 10:14AM CDT
PMD: 15.14 (+0.02)
Psychemedics Corporation Announces Record Revenues
PR Newswire - Thu Oct 30, 10:06AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced third quarter financial results for the period ended September 30, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of November 10, 2014 to be paid on November 20, 2014. This will be the Company's 73rd consecutive quarterly dividend.
PMD: 15.14 (+0.02)
Psychemedics: Once Brazilian Legislation Is Put Into Place Shares Should Rally
Bram de Haas - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PMD: 15.14 (+0.02)
Psychemedics Has Returned 13.0% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Wed Sep 17, 9:26AM CDT
SmarTrend identified a Downtrend for Psychemedics (NASDAQ
MD) on May 9th, 2014 at $14.87. In approximately 4 months, Psychemedics has returned 13.05% as of today's recent price of $12.93. PMD: 15.14 (+0.02)
Psychemedics Up 48.7% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Thu Mar 27, 9:38AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 48.74% as of today's recent price of $17.67. PMD: 15.14 (+0.02)
Psychemedics Shares Up 53.2% Since SmarTrend's Buy Recommendation (PMD)
Comtex SmarTrend(R) - Thu Mar 20, 9:11AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 53.20% as of today's recent price of $18.20. PMD: 15.14 (+0.02)
Uptrend Call Working As Psychemedics Stock Rises 50.8% (PMD)
Comtex SmarTrend(R) - Wed Mar 12, 4:51PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 50.76% as of today's recent price of $17.91. PMD: 15.14 (+0.02)
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
PMD: 15.14 (+0.02), BGMD: 0.45 (-0.02), RXDX: 6.76 (+0.04), BRLI: 28.98 (-0.05), DGX: 63.77 (+0.88), GHDX: 32.77 (-0.22)
Psychemedics Up 52.1% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Wed Mar 05, 11:04AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 52.10% as of today's recent price of $18.07. PMD: 15.14 (+0.02)
OTC Daily Alert Stock Watch - Psychemedics Corporation (NASDAQ: PMD)
WorldStockWire - Mon Sep 02, 10:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
PMD: 15.14 (+0.02)
Psychemedics Corporation Announces Top Revenue Quarter
PR Newswire - Mon Aug 05, 10:36AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2013. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 15, 2013 to be paid on August 28, 2013. This will be the Company's 68th consecutive quarterly dividend.
PMD: 15.14 (+0.02)
Psychemedics Corporation Launches New Hair Alcohol Test
PR Newswire - Mon Jul 08, 12:01PM CDT
Psychemedics Corporation (NASDAQ
MD), hair testing pioneer and global leader for over twenty-five years, announced the launch of its hair alcohol test - a test that measures average alcohol consumption over a period of approximately three months, indicates the level of alcohol use during that time period, and can provide a behavioral indication of excessive use. PMD: 15.14 (+0.02)
Sarah Ashby Promoted To VP And General Counsel At Psychemedics Corporation
PR Newswire - Tue May 14, 10:44AM CDT
Psychemedics Corporation (NASDAQ: PMD), the world's largest provider of hair analysis drug testing, today announced that Sarah Ashby has been promoted to the position of Vice President and General Counsel.
PMD: 15.14 (+0.02)
Psychemedics Corporation announces lower net income of USD822,000, but higher revenues of USD6.4m for Q1
M2 - Wed May 08, 10:28AM CDT
Drug abuse testing company Psychemedics Corporation (NasdaqCM
MD) stated on Tuesday its net income of USD822,000 or USD0.16 per diluted share, for the first quarter period ended 31 March 2013. PMD: 15.14 (+0.02)
Psychemedics Corporation Announces Record First Quarter Revenues
PR Newswire - Tue May 07, 10:33AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2013. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 17, 2013 to be paid on May 30, 2013. This will be the Company's 67th consecutive quarterly dividend.
PMD: 15.14 (+0.02)
Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test
PR Newswire - Thu Feb 28, 10:43AM CST
Psychemedics Corporation, (NASDAQ: PMD) and TruTouch Technologies, Inc. today announced that they have signed an agreement to market TruTouch's rapid optical alcohol detection and biometric test in the US. The workplace sobriety assurance solution utilizes an optical based, non-invasive near infra red sensor that quickly and accurately measures alcohol consumption. This is simply done by placing the index finger on the optical sensor and waiting as few as 10 seconds for the initial results.
PMD: 15.14 (+0.02)
Psychemedics Corporation Announces Record Revenues For 2012; Declares 66th Consecutive Quarterly Dividend
PR Newswire - Mon Feb 25, 10:57AM CST
Psychemedics Corporation (NASDAQ
MD) today announced fourth quarter and year-end financial results for the period ended December 31, 2012. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of March 7, 2013 to be paid on March 21, 2013. This will be the Company's 66th consecutive quarterly dividend. PMD: 15.14 (+0.02)
